The Valley of Dilution™

Mike Hull • September 8, 2026

Biotech founders are often taught to fear the Valley of Death: the period between promising science and a financeable product. There is another risk that receives less attention—the Valley of Dilution™. It occurs when a company raises expensive equity before key uncertainties have been reduced.

Why Premature Equity Is So Expensive

Equity is usually cheapest for the investor—and most expensive for the founder—when the company is early, uncertain, and dependent on future proof. If the same company can use grants, translational awards, sponsored research, disease-foundation funding, strategic support, or modest founder capital to reach a meaningful milestone first, its negotiating position may improve substantially.


  • Early valuation reflects unresolved scientific and commercial risk.
  • Large early rounds can create pressure to grow before product-market assumptions are tested.
  • Future financing may require increasingly large step-ups in valuation.
  • Founders can lose strategic flexibility when investors control major decisions.

What Should Be Funded before a Major Equity Round?

The objective is not to avoid venture capital. The objective is to use equity when it can accelerate a validated path rather than finance discovery of the path itself.


  • Initial customer and stakeholder discovery
  • Commercial use-case definition
  • Core IP strategy and license terms
  • Key proof-of-concept or validation milestones
  • Regulatory pathway assessment
  • Early reimbursement and market-access analysis
  • A credible development budget and financing plan

The Milestone-Value Relationship

A useful financing question is: What can we prove with the least dilutive capital that would materially change the company's value or financing options? That milestone may be a validated prototype, animal data, analytical performance, a regulatory interaction, a license, a pilot customer, or another asset-specific inflection point.

BYB Takeaway

Preserving equity is not the same as refusing investment. The goal is to cross the riskiest early milestones with the most capital-efficient funding available, then use institutional capital when it can create disproportionate value.

Before raising equity, ask: What milestone could we reach first that would make this company more valuable?

How to Commercialize University Research

By Mike Hull • September 14, 2026
Commercialization requires a second layer of work: translating the discovery into a defined use case, protectable asset, development plan, evidence package, and funding strategy that a customer, licensee, investor, or strategic partner can act on.

What Is a Biotech Commercialization Plan?

By Mike Hull • September 13, 2026
It is the operating logic that explains how a scientific asset can move from its current state to a product that can be funded, licensed, approved, adopted, reimbursed, partnered, or sold.

How Much Validation Do You Need Before Raising Capital?

By Mike Hull • September 12, 2026
There is no universal amount of validation required before a biotech company raises capital. Investors fund risk, so a company does not need every question answered.

License Your Technology or Start a Biotech Company?

By Mike Hull • September 11, 2026
For university inventors, one of the most important commercialization decisions is whether to license the technology directly to an established company or form a startup to develop it further.

The Bootstrap Score™

By Mike Hull • September 10, 2026
The Bootstrap Score™ is a practical framework for asking a more useful question: how much of the commercial risk has been reduced around the science?

The Commercialization Gap™

By Mike Hull • September 9, 2026
A paper can establish an important scientific finding, while a buyer, investor, regulator, licensee, or strategic partner may still see substantial unanswered risk.

The Bootstrap Flywheel™

By Mike Hull • September 7, 2026
The Bootstrap Flywheel™ is a different model: use each small de-risking step to make the next step easier, cheaper, and more credible.

Biotech Funding Sequence: What Money Should You Raise First?

By Mike Hull • September 6, 2026
The most important financing question for an early biotech company is often not how much money to raise. It is what type of money should fund the next milestone.

When Should a Biotech Startup Raise Venture Capital?

By Mike Hull • September 5, 2026
Venture capital is not inherently too early or too expensive. It becomes expensive when founders use it to answer questions that could have been answered first with smaller or less dilutive resources.

What Is NIH TABA?

By Mike Hull • September 4, 2026
NIH Technical and Business Assistance—commonly called TABA—is designed to help SBIR and STTR recipients address product-development and commercialization needs that are often outside the core scientific aims of the award.